Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Status: | Recruiting |
---|---|
Conditions: | Breast Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 5/6/2017 |
Start Date: | August 2013 |
End Date: | August 2028 |
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
This randomized phase III trial studies standard or comprehensive radiation therapy in
treating patients with early-stage breast cancer who have undergone surgery. Radiation
therapy uses high-energy x rays to kill tumor cells. It is not yet known whether
comprehensive radiation therapy is more effective than standard radiation therapy in
treating patients with breast cancer
treating patients with early-stage breast cancer who have undergone surgery. Radiation
therapy uses high-energy x rays to kill tumor cells. It is not yet known whether
comprehensive radiation therapy is more effective than standard radiation therapy in
treating patients with breast cancer
PRIMARY OBJECTIVES:
To evaluate whether the addition of chest wall + regional nodal radiation therapy (XRT)
after mastectomy or breast + regional nodal XRT after breast conserving surgery will
significantly reduce the rate of events for invasive breast cancer recurrence-free interval
(IBC-RFI) in patients who present with histologically positive axillary nodes but convert to
histologically negative axillary nodes following neoadjuvant chemotherapy.
SECONDARY OBJECTIVES:
I. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or
breast + regional nodal XRT after breast conserving surgery will significantly prolong
overall survival (OS) in patients who present with histologically positive axillary nodes
but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.
II. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or
breast + regional nodal XRT after breast conserving surgery will significantly reduce the
rates of events for local-regional recurrence-free interval (LRRFI) in patients who present
with histologically positive axillary nodes but convert to histologically negative axillary
nodes following neoadjuvant chemotherapy.
III. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or
breast + regional nodal XRT after breast conserving surgery will significantly reduce the
rate of events for distant recurrence-free interval (DRFI) in patients who present with
histologically positive axillary nodes but convert to histologically negative axillary nodes
following neoadjuvant chemotherapy.
IV. To compare the rates of disease-free survival (DFS)-ductal carcinoma in situ (DCIS) by
treatment arm.
V. To compare the rates of second primary cancer (SPC) by treatment arm.
VI. To compare the effect of adding XRT on the cosmetic outcomes in mastectomy patients who
have had reconstruction.
VII. To compare the effect of adding XRT on quality of life including arm problems,
lymphedema, pain, and fatigue.
VIII. To evaluate the toxicity associated with each of the radiation therapy regimens.
IX. To determine whether computed tomography (CT)-based conformal methods
(intensity-modulated radiation therapy [IMRT] and 3-dimensional conformal radiation therapy
[3DCRT]) for chestwall + regional nodal XRT post mastectomy and regional nodal XRT with
breast XRT following breast conserving surgery are feasible in a multi-institutional setting
and whether dose-volume analyses can be established to assess treatment adequacy and to
develop normal tissue complication probabilities (NTCP) for the likelihood of toxicity.
X. To compare the effect of XRT in patients receiving mastectomy and in patients receiving
lumpectomy.
XI. To examine the role of proliferation measures as a prognosticator for patients with
residual disease after neoadjuvant chemotherapy.
XII. To develop predictors of the degree of reduction in local regional recurrence (LRR).
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM 1: Patients are assigned to 1 of 2 treatment groups.
GROUP 1A: Lumpectomy patients undergo whole breast radiation therapy using IMRT or 3DCRT
once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy
cavity once daily 5 days a week for 1-1/2 weeks.
GROUP 1B: Mastectomy patients do not undergo radiation therapy.
ARM 2: Patients are assigned to 1 of 2 treatment groups.
GROUP 2A: Lumpectomy patients undergo regional nodal radiation therapy with whole breast
radiation therapy using IMRT or 3DCRT once daily 5 days a week for 5 weeks followed by a
radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
GROUP 2B: Mastectomy patients undergo regional nodal radiation therapy and chestwall XRT
using IMRT or 3DCRT once daily 5 days a week for 5 weeks.
All patients also receive systemic therapy as planned (hormonal therapy for patients with
hormone-receptor positive breast cancer and trastuzumab or other anti-human epidermal growth
factor receptor 2 [HER2] therapy for patients with breast cancer that is HER2-positive).
After completion of study treatment, patients are followed up at 6, 12, 18, and 24 months
and then yearly for 8 years.
To evaluate whether the addition of chest wall + regional nodal radiation therapy (XRT)
after mastectomy or breast + regional nodal XRT after breast conserving surgery will
significantly reduce the rate of events for invasive breast cancer recurrence-free interval
(IBC-RFI) in patients who present with histologically positive axillary nodes but convert to
histologically negative axillary nodes following neoadjuvant chemotherapy.
SECONDARY OBJECTIVES:
I. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or
breast + regional nodal XRT after breast conserving surgery will significantly prolong
overall survival (OS) in patients who present with histologically positive axillary nodes
but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.
II. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or
breast + regional nodal XRT after breast conserving surgery will significantly reduce the
rates of events for local-regional recurrence-free interval (LRRFI) in patients who present
with histologically positive axillary nodes but convert to histologically negative axillary
nodes following neoadjuvant chemotherapy.
III. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or
breast + regional nodal XRT after breast conserving surgery will significantly reduce the
rate of events for distant recurrence-free interval (DRFI) in patients who present with
histologically positive axillary nodes but convert to histologically negative axillary nodes
following neoadjuvant chemotherapy.
IV. To compare the rates of disease-free survival (DFS)-ductal carcinoma in situ (DCIS) by
treatment arm.
V. To compare the rates of second primary cancer (SPC) by treatment arm.
VI. To compare the effect of adding XRT on the cosmetic outcomes in mastectomy patients who
have had reconstruction.
VII. To compare the effect of adding XRT on quality of life including arm problems,
lymphedema, pain, and fatigue.
VIII. To evaluate the toxicity associated with each of the radiation therapy regimens.
IX. To determine whether computed tomography (CT)-based conformal methods
(intensity-modulated radiation therapy [IMRT] and 3-dimensional conformal radiation therapy
[3DCRT]) for chestwall + regional nodal XRT post mastectomy and regional nodal XRT with
breast XRT following breast conserving surgery are feasible in a multi-institutional setting
and whether dose-volume analyses can be established to assess treatment adequacy and to
develop normal tissue complication probabilities (NTCP) for the likelihood of toxicity.
X. To compare the effect of XRT in patients receiving mastectomy and in patients receiving
lumpectomy.
XI. To examine the role of proliferation measures as a prognosticator for patients with
residual disease after neoadjuvant chemotherapy.
XII. To develop predictors of the degree of reduction in local regional recurrence (LRR).
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM 1: Patients are assigned to 1 of 2 treatment groups.
GROUP 1A: Lumpectomy patients undergo whole breast radiation therapy using IMRT or 3DCRT
once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy
cavity once daily 5 days a week for 1-1/2 weeks.
GROUP 1B: Mastectomy patients do not undergo radiation therapy.
ARM 2: Patients are assigned to 1 of 2 treatment groups.
GROUP 2A: Lumpectomy patients undergo regional nodal radiation therapy with whole breast
radiation therapy using IMRT or 3DCRT once daily 5 days a week for 5 weeks followed by a
radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
GROUP 2B: Mastectomy patients undergo regional nodal radiation therapy and chestwall XRT
using IMRT or 3DCRT once daily 5 days a week for 5 weeks.
All patients also receive systemic therapy as planned (hormonal therapy for patients with
hormone-receptor positive breast cancer and trastuzumab or other anti-human epidermal growth
factor receptor 2 [HER2] therapy for patients with breast cancer that is HER2-positive).
After completion of study treatment, patients are followed up at 6, 12, 18, and 24 months
and then yearly for 8 years.
Inclusion Criteria:
- The patient must have signed and dated an Institutional Review Board (IRB)-approved
consent form that conforms to federal and institutional guidelines
- The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status
of 0 or 1
- Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before
neoadjuvant therapy); clinical axillary nodal involvement can be assessed by
palpation, ultrasound, CT scan, magnetic resonance imaging (MRI), positron emission
tomography (PET) scan, or PET/CT scan
- Patient must have had pathologic confirmation of axillary nodal involvement at
presentation (before neoadjuvant therapy) based on either a positive fine needle
aspirate (FNA) (demonstrating malignant cells) or positive core needle biopsy
(demonstrating invasive adenocarcinoma); the FNA or core needle biopsy can be
performed either by palpation or by image guidance; documentation of axillary nodal
positivity by sentinel node biopsy (before neoadjuvant therapy) is not permitted
- Patients must have had estrogen receptor (ER) analysis performed on the primary
breast tumor before neoadjuvant therapy according to current American Society of
Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline
recommendations for hormone receptor testing; if negative for ER, assessment of
progesterone receptor (PgR) must also be performed according to current ASCO/CAP
guideline recommendations for hormone receptor testing (http://www.asco.org)
- Patients must have had HER2 testing performed on the primary breast tumor before
neoadjuvant chemotherapy according to the current ASCO/CAP guideline recommendations
for human epidermal growth factor receptor 2 testing in Breast Cancer
(http://www.asco.org); patients who have a primary tumor that is either HER2-positive
or HER2-negative are eligible
- Patient must have completed a minimum of 12 weeks of standard neoadjuvant
chemotherapy consisting of an anthracycline and/or taxane-based regimen
- For patients who receive adjuvant chemotherapy after surgery, a maximum of 12 weeks
of intended chemotherapy may be administered but must be completed before
randomization; (if treatment delays occur, chemotherapy must be completed within 14
weeks); the dose and schedule of the adjuvant chemotherapy are at the investigator's
discretion; Note: It is preferred that all intended chemotherapy be administered in
the neoadjuvant setting
- Patients with HER2-positive tumors must have received neoadjuvant trastuzumab or
other anti-HER2 therapy (either with all or with a portion of the neoadjuvant
chemotherapy regimen), unless medically contraindicated
- At the time of definitive surgery, all removed axillary nodes must be histologically
free from cancer; acceptable procedures for assessment of axillary nodal status at
the time of surgery include:
- Axillary node dissection
- Sentinel node biopsy alone or
- Sentinel node biopsy followed by axillary node dissection
- Note: Patients are eligible whether there is residual invasive carcinoma in the
surgical breast specimen or whether there is evidence of pathologic complete
response; patients who are found to be pathologically node-positive at the time
of surgery, based on sentinel node biopsy alone, are candidates for A011202, a
study developed by the Alliance in Oncology, an NCI Cooperative Group; if
A011202 is open at the investigator's institution, patients should be approached
about participating in the A011202 study
- Patients with pathologic staging of ypN0(i+) or ypN0(mol+) are eligible (Note:
Postneoadjuvant therapy is designated with a "yp" prefix.)
- Patient who have undergone either a total mastectomy or a lumpectomy are eligible
- For patients who undergo lumpectomy, the margins of the resected specimen or
re-excision must be histologically free of invasive tumor and DCIS as determined by
the local pathologist; additional operative procedures may be performed to obtain
clear margins; if tumor is still present at the resected margin after re-excision(s),
the patient must undergo total mastectomy to be eligible; (patients with margins
positive for lobular carcinoma in situ [LCIS] are eligible without additional
resection)
- For patients who undergo mastectomy, the margins must be histologically free of
residual (microscopic or gross) tumor
- The interval between the last surgery for breast cancer (including re-excision of
margins) and randomization must be no more than 56 days; also, if adjuvant
chemotherapy was administered, the interval between the last chemotherapy treatment
and randomization must be no more than 56 days
- The patient must have recovered from surgery with the incision completely healed and
no signs of infection
- If adjuvant chemotherapy was administered, chemotherapy-related toxicity that may
interfere with delivery of radiation therapy should have resolved
Exclusion Criteria:
- Definitive clinical or radiologic evidence of metastatic disease
- T4 tumors including inflammatory breast cancer
- Documentation of axillary nodal positivity before neoadjuvant therapy by sentinel
node biopsy alone
- N2 or N3 disease detected clinically or by imaging
- Patients with histologically positive axillary nodes post neoadjuvant therapy
- Patients with microscopic positive margins after definitive surgery
- Synchronous or previous contralateral invasive breast cancer or DCIS; (patients with
synchronous and/or previous contralateral LCIS are eligible)
- Any prior history, not including the index cancer, of ipsilateral invasive breast
cancer or ipsilateral DCIS treated with radiation therapy; (patients with synchronous
or previous ipsilateral LCIS are eligible)
- History of non-breast malignancies (except for in situ cancers treated only by local
excision and basal cell and squamous cell carcinomas of the skin) within 5 years
prior to randomization
- Any radiation therapy for the currently diagnosed breast cancer prior to
randomization
- Any continued use of sex hormonal therapy, e.g., birth control pills, ovarian hormone
replacement therapy; patients are eligible if these medications are discontinued
prior to randomization
- Prior breast or thoracic radiation therapy (RT) for any condition
- Active collagen vascular disease, specifically dermatomyositis with a creatinine
phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus
erythematosus, or scleroderma
- Pregnancy or lactation at the time of study entry; (Note: Pregnancy testing must be
performed within 2 weeks prior to randomization according to institutional standards
for women of childbearing potential)
- Other non-malignant systemic disease that would preclude the patient from receiving
study treatment or would prevent required follow-up
- Psychiatric or addictive disorders or other conditions that, in the opinion of the
investigator, would preclude the patient from meeting the study requirements
We found this trial at
497
sites
601 South Sherman Street
Spokane, Washington 99202
Spokane, Washington 99202
(509) 228-1000
Principal Investigator: Janice N. Kim
Phone: 800-804-8824
Cancer Care Northwest - Spokane South Cancer Care Northwest is the Inland Northwest’s premier cancer...
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Benny J. Liem
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Shayna L. Showalter
Phone: 434-243-6322
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
Duarte, California 91010
(626) 256-4673
Principal Investigator: Lily L. Lai
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
Click here to add this to my saved trials
3300 Gallows Road
Falls Church, Virginia 22042
Falls Church, Virginia 22042
(703) 776-4001
Principal Investigator: Ashish K. Chawla
Phone: 703-208-6650
Inova Fairfax Hospital Inova Fairfax Hospital, Inova's flagship hospital, is an 833-bed, nationally recognized regional...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Samir Narayan
Phone: 734-712-4673
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Judith L. Lightsey
Phone: 352-273-8675
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Srinivasan Vijayakumar
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: V. S. Klimberg
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Christiane M. Burnison
Phone: 310-423-8965
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
620 John Paul Jones Cir
Portsmouth, Virginia 23708
Portsmouth, Virginia 23708
(757) 953-5008
Principal Investigator: Andrew S. Camarata
Phone: 757-953-5939
Naval Medical Center - Portsmouth Naval Medical Center Portsmouth, Virginia has proudly served the military...
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
Providence, Rhode Island 02903
401-444-4000
Principal Investigator: Kara L. Leonard
Phone: 401-444-1488
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Harry D. Bear
Phone: 804-628-1939
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Richard L. Crownover
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
Click here to add this to my saved trials
34800 Bob Wilson Dr,
San Diego, California 92134
San Diego, California 92134
(619) 532-6400
Principal Investigator: Harvey B. Wilds
Phone: 619-532-8712
Naval Medical Center - San Diego We are the largest and most comprehensive military healthcare...
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Janice N. Kim
Phone: 800-804-8824
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Janice N. Kim
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
Sioux Falls, South Dakota 57108
(605) 322-4700
Principal Investigator: Amy K. Krie
Phone: 888-634-7268
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
Click here to add this to my saved trials
'Ewa Beach, Hawaii 96706
Principal Investigator: Kenneth N. Sumida
Phone: 808-524-6115
Click here to add this to my saved trials
Abilene, Texas 79606
Principal Investigator: Vivek S. Kavadi
Phone: 281-277-5200
Click here to add this to my saved trials
1 Akron General Ave
Akron, Ohio 44307
Akron, Ohio 44307
(330) 344-6000
Principal Investigator: Andrew H. Fenton
Phone: 330-344-6348
Akron General Medical Center It
Click here to add this to my saved trials
Akron, Ohio 44304
Principal Investigator: Desiree E. Doncals
Phone: 330-375-6101
Click here to add this to my saved trials
Albert Lea, Minnesota 56007
Principal Investigator: Robert W. Mutter
Phone: 855-776-0015
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Benny J. Liem
Phone: 505-925-0366
Click here to add this to my saved trials
4650 Jefferson Lane Northeast
Albuquerque, New Mexico 87109
Albuquerque, New Mexico 87109
Principal Investigator: Benny J. Liem
Phone: 505-925-0366
Click here to add this to my saved trials
Alexandria, Virginia 22304
Principal Investigator: Jane Grayson
Phone: 703-776-2580
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Samir Narayan
Phone: 734-712-4673
Click here to add this to my saved trials
Altamonte Springs, Florida 32701
Principal Investigator: Carlos A. Alemany
Phone: 407-303-2090
Click here to add this to my saved trials
Amarillo, Texas 79106
Principal Investigator: Daniel Arsenault
Phone: 806-212-1985
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Benjamin B. Bridges
Phone: 208-381-3376
Click here to add this to my saved trials
Anderson, Indiana 46016
Principal Investigator: Alexander M. Yeh
Phone: 765-646-8358
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Lori J. Pierce
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
Annapolis, Maryland 21401
Principal Investigator: Mary E. Young
Phone: 443-481-1320
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Hamied R. Rezazadeh
Phone: 877-405-6866
Click here to add this to my saved trials
Appleton, Wisconsin 54911
Principal Investigator: Editha (Edie) A. Krueger
Phone: 920-380-1500
Click here to add this to my saved trials
Appleton, Wisconsin 54911
Principal Investigator: Editha (Edie) A. Krueger
Phone: 920-380-1500
Click here to add this to my saved trials
Appleton, Wisconsin 54911
Principal Investigator: Editha (Edie) A. Krueger
Phone: 920-380-1500
Click here to add this to my saved trials
Arlington, Texas 76014
Principal Investigator: Vivek S. Kavadi
Phone: 281-277-5200
Click here to add this to my saved trials
5665 Peachtree Dunwoody Rd NE
Atlanta, Georgia 30342
Atlanta, Georgia 30342
(678) 843-7001
Principal Investigator: Mylin A. Torres
Phone: 404-778-1868
Saint Joseph's Hospital of Atlanta Founded by the Sisters of Mercy in 1880, Saint Joseph
Click here to add this to my saved trials
1968 Peachtree Rd NW
Atlanta, Georgia 30309
Atlanta, Georgia 30309
(404) 605-5000
Principal Investigator: Adam W. Nowlan
Phone: 404-425-7943
Piedmont Hospital For more than a century, Piedmont Healthcare has been a recognized leader in...
Click here to add this to my saved trials
Atlanta, Georgia 30303
Principal Investigator: Mylin A. Torres
Phone: 404-778-1868
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Mylin A. Torres
Phone: 404-778-1868
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Mylin A. Torres
Phone: 404-778-1868
Click here to add this to my saved trials
Atlantis, Florida 33462
Principal Investigator: Beth-Ann Lesnikoski
Phone: 561-964-2662
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 253-403-2394
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
13001 E. 17th Pl.
Aurora, Colorado 80045
Aurora, Colorado 80045
303-724-5000
Principal Investigator: Rachel A. Rabinovitch
Phone: 720-848-0650
University of Colorado Cancer Center - Anschutz Cancer Pavilion The University of Colorado Denver |...
Click here to add this to my saved trials
Austin, Texas 78731
Principal Investigator: Vivek S. Kavadi
Phone: 281-277-5200
Click here to add this to my saved trials
Austin, Texas 78705
Principal Investigator: Vivek S. Kavadi
Phone: 281-277-5200
Click here to add this to my saved trials
Austin, Texas 78745
Principal Investigator: Vivek S. Kavadi
Phone: 281-277-5200
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Geoffrey A. Neuner
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Steven J. Feigenberg
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
Click here to add this to my saved trials
Baltimore, Maryland 21237
Principal Investigator: Edward C. McCarron
Phone: 443-777-7364
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Jean L. Wright
Phone: 202-243-2373
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
155 5th St NE
Barberton, Ohio 44203
Barberton, Ohio 44203
(330) 615-3000
Principal Investigator: Desiree E. Doncals
Phone: 330-375-6101
Summa Barberton Hospital Summa Barberton Hospital is a full member of Summa Health System and...
Click here to add this to my saved trials
136 Mountainview Blvd
Basking Ridge, New Jersey 7920
Basking Ridge, New Jersey 7920
(908) 542-3000
Principal Investigator: Beryl McCormick
Phone: 212-639-7202
Memorial Sloan-Kettering Cancer Center - Basking Ridge At Memorial Sloan Kettering Basking Ridge, we offer...
Click here to add this to my saved trials
Baton Rouge, Louisiana 70806
Principal Investigator: Bridgette M. Collins-Burow
Phone: 504-988-6121
Click here to add this to my saved trials
Baton Rouge, Louisiana 70815
Principal Investigator: M. G. Fort
Phone: 225-231-5296
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Robert R. Shenk
Phone: 800-641-2422
Click here to add this to my saved trials
Beaver, Pennsylvania 15009
Principal Investigator: Sushil Beriwal
Phone: 412-647-2811
Click here to add this to my saved trials
Bedford, Texas 76022
Principal Investigator: Vivek S. Kavadi
Phone: 281-277-5200
Click here to add this to my saved trials
Bel Air, Maryland 21014
Principal Investigator: Steven J. Feigenberg
Phone: 800-888-8823
Click here to add this to my saved trials
Bellevue, Washington 98004
Principal Investigator: John A. Keech
Phone: 253-403-2394
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18015
Principal Investigator: Nimisha Deb
Phone: 610-954-3582
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Jennifer F. De Los Santos
Phone: 800-828-8816
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-234-6161
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Samir Narayan
Phone: 734-712-4673
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Faina Nakhlis
Phone: 617-983-7000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Ariel E. Hirsch
Phone: 617-638-8265
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
425 Jack Martin Blvd
Bricktown, New Jersey 08724
Bricktown, New Jersey 08724
Principal Investigator: Douglas A. Miller
Phone: 732-206-8384
Click here to add this to my saved trials
4802 10th Ave
Brooklyn, New York 11219
Brooklyn, New York 11219
(718) 283-6000
Principal Investigator: David M. Berlach
Phone: 718-765-2500
Maimonides Medical Center At 103 years old, Maimonides Medical Center remains a vital and thriving...
Click here to add this to my saved trials
Click here to add this to my saved trials
Brownstown Charter Township, Michigan 48183
Principal Investigator: Thomas J. Doyle
Phone: 313-916-1784
Click here to add this to my saved trials
Burlingame, California 94010
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: Patrick J. Flynn
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
Click here to add this to my saved trials
Camden, New Jersey 08103
Principal Investigator: Ashish B. Patel
Phone: 856-325-6757
Click here to add this to my saved trials
Cameron Park, California 95682
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
Click here to add this to my saved trials
2600 Sixth St. SW
Canton, Ohio 44710
Canton, Ohio 44710
330.363.4908
Principal Investigator: Shruti Trehan
Phone: 330-363-6891
Aultman Health Foundation The Aultman Foundation will raise and administer funds in order to support...
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: James L. Wade
Phone: 217-876-4740
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
Carmel, New York 10512
Principal Investigator: Gregory J. Zanieski
Phone: 845-483-6483
Click here to add this to my saved trials
Carrollton, Georgia 30117
Principal Investigator: James R. Bland
Phone: 770-836-9824
Click here to add this to my saved trials
Castro Valley, California 94546
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Jennifer L. Harper
Phone: 843-792-9321
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
Charleston, South Carolina 29401
Principal Investigator: Steven A. Akman
Phone: 843-720-8386
Click here to add this to my saved trials
Charleston, South Carolina 29414
Principal Investigator: Steven A. Akman
Phone: 843-720-8386
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Principal Investigator: Hadley J. Sharp
Phone: 800-804-9376
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Principal Investigator: Nasfat Shehadeh
Phone: 704-384-5369
Click here to add this to my saved trials
Charlotte, North Carolina 28262
Principal Investigator: Hadley J. Sharp
Phone: 704-355-2884
Click here to add this to my saved trials
Charlotte, North Carolina 28210
Principal Investigator: Hadley J. Sharp
Phone: 704-355-2884
Click here to add this to my saved trials
232 S Woods Mill Rd
Chesterfield, Missouri 63017
Chesterfield, Missouri 63017
(314) 205-6491
Principal Investigator: Donald F. Busiek
Phone: 314-205-6936
Saint Luke's Hospital St. Luke's Hospital, located in Chesterfield, Missouri, is a regional healthcare provider...
Click here to add this to my saved trials
1969 W Ogden Ave
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 864-6000
Principal Investigator: Thomas E. Lad
Phone: 312-864-6000
John H. Stroger, Jr. Hospital of Cook County The Level 1 Trauma Center is one...
Click here to add this to my saved trials
1200 West Harrison Stree
Chicago, Illinois 60607
Chicago, Illinois 60607
(312) 996-4350
Principal Investigator: Kent F. Hoskins
Phone: 312-355-3046
Univ of Illinois A major research university in the heart of one of the world's...
Click here to add this to my saved trials